pharmaceuticals
pharmaceuticals Articles
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published:
Regeneron Pharmaceuticals, one of the front-runners for the development of a COVID-19 treatment, released an update on its antibody drug combination on Monday.
Published:
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.
Published:
When Merck & Co. (NYSE: MRK) reported its second-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had earnings per share (EPS) of $1.37 and...
Published:
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Published:
Eastman Kodak is making a fresh move to manufacturing drug ingredients with a $765 million government loan under the direction of President Trump.
Published:
Kodak, once a giant in photography, received a $765 million federal loan to begin building a pharmaceutical business.
Published:
Pfizer released a better than expected second-quarter earnings report and increased its guidance before the markets opened on Tuesday.
Published:
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Published:
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
Published:
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
Published:
GlaxoSmithKline has announced that it is acquiring a 10% stake in the German biopharma firm CureVac.
Published:
BioNTech and Pfizer are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.
Published: